Naslov
Role of the proton pump inhibitors in Helicobacter pylori eradication: results from the European registry on H. pylori management (HP-EUREG)

Autori
M. Castro Fernandez, M. Pabón-Carrasco, A. Keco- Huerga1, Á. Pérez-Aísa, D. Vaira, L. Jonaitis, B. Tepes, D. Bordin, A. Lucendo, L. Vologzhanina, L. Bujanda, N. Brglez Jurecic, A. Lanas, M. Leja, E. Mammadov, U. Mahmudov, M. Caldas, L. Rodrigo, F. Lerang, G. Fadieienko, R. Abdulkhakov, J.M. Huguet Malavés, O. Zaytsev, T. Ilchishina, L. Fernández- Salazar, A. Silkanovna Sarsenbaeva, I. Bakulin, A.G. Gravina, M. Perona, S. Alekseenko, J. Barrio, M. Areia, Ó. Nuñez, P. Bogomolov, B.J. Gomez Rodriguez, M. Dominguez-Cajal, J. Gomez Camarero, S. Georgopoulos, P. Almela Notari, Ante Tonkić, R. Pellicano, H. Simsek, L. Kunovský, A. Gasbarrini, J.M. Botargues Bote, I. Puig, O. Perez Nyssen, F. Mégraud, C. O’Morain, J. P. Gisbert

Kolaboracija
Hp-EuReg Investigators

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
United European Gastroenterology Journal 10(2022)S8 / - , 2022, 561-562

Skup
30th United European Gastroenterology Week

Mjesto i datum
Beč, Austrija, 08.10.2022. - 11.10.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Helicobacter pylori ; proton pump inhibitors

Sažetak
Introduction: Management of Helicobacter pylori infection (H. pylori) re-quires co- treatment with proton pump inhibitors (PPIs) and the use of an- tibiotics to achieve successful eradicationAims & Methods: To evaluate the role of PPIs in the eradication of H. py-lori, based on the “European Registry onHelicobacter pylori Management” (Hp- EuReg).The Hp-EuReg is a multicentre, prospective, non-interventional, registry assessing decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice. Countries recruiting more than 1, 000 patients were included. Effectiveness was assessed by modi- fied intention-to-treat (mITT). Data were quality reviewed.Results: Overall, 22, 078 patients from 5 countries were analysed. Optimal (»90%) first-line mITT effectiveness was achieved with the following treatments: 14-day clarithromycin- amoxicillin- bismuth quadruple therapy, and 14- day metronidazole-tetracycline-bismuth quadruple therapy, both inde-pendently of the PPI dose prescribed ; in all 10- or 14-day therapies with high-dose PPIs (except with standard 10-day triple therapy) ; in 10-day se-quential and 10- day quadruple clarithromycin-amoxicillin- bismuth, and 10-day quadruple metronidazole- tetracycline- bismuth with standard-dose PPIs. None of the 7-day therapies achieved optimal cure rates re-gardless of the PPI dose used. The PPI dose was significantly associated with the effectiveness of: 10- or 14- day standard triple and quadruple con-comitant therapies, and 10-day quadruple sequential and metronidazole-tetracycline-bismuth therapies. Table 1 details the mITT effectiveness by duration and PPI dose used.Conclusion: In first-lineH. pylori treatment, ≥90% effectiveness is obtained with standard-dose PPIs in 10-day sequential and 10- or 14-day bismuth quadruple therapies and with high-dose PPIs in all 10- or 14-day therapies except with standard 10-day triple therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA